论文部分内容阅读
目的探讨泮托拉唑抑制胃溃疡胃酸分泌的临床疗效。方法选取2013年1月—2014年9月桂林中西医结合医院收治的胃溃疡患者70例,按随机数字表法将患者分为研究组与对照组,各35例。研究组患者予以泮托拉唑治疗,对照组患者予以法莫替丁治疗。观察两组患者临床疗效、治疗前后视觉模拟评分法(VAS)评分、幽门螺杆菌(HP)感染情况及不良反应发生情况。结果研究组患者总有效率高于对照组,差异有统计学意义(P<0.05);治疗前两组患者VAS评分比较,差异无统计学意义(P>0.05),治疗后研究组患者VAS评分低于对照组,差异有统计学意义(P<0.05);治疗前两组患者HP感染率比较,差异无统计学意义(P>0.05),治疗后研究组患者HP感染率低于对照组,差异有统计学意义(P<0.05);两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论泮托拉唑抑制胃溃疡胃酸分泌的临床疗效显著,可降低患者疼痛程度,减少HP感染的发生,且不良反应小。
Objective To investigate the clinical efficacy of pantoprazole in inhibiting gastric acid secretion in gastric ulcer. Methods Seventy patients with gastric ulcer admitted from January 2013 to September 2014 in Guilin Hospital of Integrated Traditional Chinese and Western Medicine were divided into study group and control group according to random number table. Patients in the study group were treated with pantoprazole, and patients in the control group were treated with famotidine. The clinical efficacy, visual analogue scale (VAS) score, Helicobacter pylori (HP) infection and adverse reactions before and after treatment were observed in both groups. Results The total effective rate of the study group was higher than that of the control group (P <0.05). There was no significant difference in the VAS score between the two groups before treatment (P> 0.05). After treatment, the VAS score (P <0.05). There was no significant difference in HP infection rate between the two groups before treatment (P> 0.05). After treatment, the HP infection rate in the study group was lower than that in the control group, The difference was statistically significant (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusions Pantoprazole has a significant clinical effect of inhibiting gastric acid secretion in gastric ulcer, which can reduce the degree of pain in patients and reduce the incidence of HP infection, with a small adverse reaction.